Opendata, web and dolomites


Novel viral therapy through targeting DNA repair

Total Cost €


EC-Contrib. €






 NOVITREP project word cloud

Explore the words cloud of the NOVITREP project. It provides you a very rough idea of what is the project "NOVITREP" about.

cycle    threatening    revealed    disturbs    reduce    public    lesions    secure    prevent    world    plan    health    networks    microcephaly    agency    repair    diseases    oxidative    infected    fever    cancer    human    surprise    made    ongoing    host    global    viruses    cell    company    anti    mechanism    dna    therapeutic    cchfv    congo    outbreak    genetic    discover    genecadd    optimize    proof    drug    potent    action    babies    replication    damage    outbreaks    prevented    demonstrating    therapy    exists    explore    ebola    sweden    epidemics    suggesting    power    individuals    strategy    therapeutics    causal    treatments    investigation    grant    newly    zikv    hemorrhagic    rna    foundation    infectious    antiviral    potently    virus    acquired    ip    resistance    erc    inhibitors    cells    western    tool    relationship    proteins    perform    life    born    constant    market    zoonotic    viral    natural    internationally    crimean    business    ebov    therapies    zika    pose    pathogenic    income    battle    causing   

Project "NOVITREP" data sheet

The following table provides information about the project.


Organization address
address: Nobels Vag 5
postcode: 17177

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-07-01   to  2018-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 139˙162.00


 Project objective

Natural epidemics and outbreaks of emerging infectious diseases are a growing problem internationally. RNA viruses remain under constant attention due to the recent Zika virus (ZIKV) outbreak with potential causal relationship with microcephaly of newly born babies and Ebola virus (EBOV) and Crimean-Congo hemorrhagic fever virus (CCHFV) causing life threatening hemorrhagic fever, demonstrating how zoonotic viruses pose a major global health concern. There is an ongoing need to discover novel therapies to battle these pathogenic viruses given that no specific therapy exists. Developing new antiviral treatments by targeting host cell proteins needed in the viral life cycle is an emerging strategy to improve therapeutic power and reduce acquired drug resistance.

Based on the results from the ERC grant Genetic Networks as a tool for anti-Cancer Drug Development (GENECADD), we have developed potent inhibitors to DNA repair proteins that disturbs repair of oxidative DNA lesions. To our surprise, we observed, in collaboration with Public Health Agency of Sweden, that these inhibitors potently prevent ZIKV, EBOV and CCHFV viral replication in human cells, suggesting that these inhibitors may be used as antiviral therapeutics. Further investigation into the possible mechanism of action revealed that our inhibitors prevented the repair of oxidative damage to RNA.

Here, the overall aim is to (1) further develop and optimize our inhibitors as a novel antiviral target and demonstrate proof of concept, (2) explore and secure IP (3) develop a business plan and (4) perform a market analysis. The overall goal is to develop general antiviral treatments made available to virus-infected individuals through a public foundation in low-income areas or through a company in the Western world.


year authors and title journal last update
List of publications.
2018 Torkild Visnes, Armando Cázares-Körner, Wenjing Hao, Olov Wallner, Geoffrey Masuyer, Olga Loseva, Oliver Mortusewicz, Elisée Wiita, Antonio Sarno, Aleksandr Manoilov, Juan Astorga-Wells, Ann-Sofie Jemth, Lang Pan, Kumar Sanjiv, Stella Karsten, Camilla Gokturk, Maurice Grube, Evert J. Homan, Bishoy M. F. Hanna, Cynthia B. J. Paulin, Therese Pham, Azita Rasti, Ulrika Warpman Berglund, Catharina von Nicolai, Carlos Benitez-Buelga, Tobias Koolmeister, Dag Ivanic, Petar Iliev, Martin Scobie, Hans E. Krokan, Pawel Baranczewski, Per Artursson, Mikael Altun, Annika Jenmalm Jensen, Christina Kalderén, Xueqing Ba, Roman A. Zubarev, Pål Stenmark, Istvan Boldogh, Thomas Helleday
Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation
published pages: 834-839, ISSN: 0036-8075, DOI: 10.1126/science.aar8048
Science 362/6416 2019-09-04

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVITREP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVITREP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  


The Mass Politics of Disintegration

Read More  

GTBB (2019)

General theory for Big Bayes

Read More